Allarity Therapeutics (ALLR) Non-Current Deffered Revenue (2020 - 2022)

Allarity Therapeutics (ALLR) has 3 years of Non-Current Deffered Revenue data on file, last reported at $1.1 million in Q4 2022.

• Quarterly Non-Current Deffered Revenue rose 10.62% year-over-year to $1.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.1 million (up 10.62% YoY) and the FY2022 annual result came in at $1.1 million, up 10.62% from the prior year.
• Non-Current Deffered Revenue climbed to $1.1 million in Q4 2022, from $1.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q4 2022 to a low of $880000.0 in Q4 2020.
• A 3-year average of $988666.7 and a median of $992000.0 in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue advanced 11.25% — and 2022, when it grew 10.62%.
• Tracing ALLR's Non-Current Deffered Revenue over 3 years: stood at $880000.0 in 2020, then gained by 11.25% to $979000.0 in 2021, then climbed by 10.62% to $1.1 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $1.1 million (Q4 2022), $1.0 million (Q2 2022), and $1.0 million (Q1 2022), per Business Quant data.